213 related articles for article (PubMed ID: 34605017)
1. Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia: a population-based study in the Netherlands, 1989-2018.
Amaador K; Kersten MJ; Visser O; Brink M; Posthuma EFM; Minnema MC; Vos JMI; Dinmohamed AG
Br J Haematol; 2022 Feb; 196(3):660-669. PubMed ID: 34605017
[TBL] [Abstract][Full Text] [Related]
2. Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia, 2000-2016.
Dalal NH; Dores GM; Curtis RE; Linet MS; Morton LM
Br J Haematol; 2020 Jun; 189(6):1107-1118. PubMed ID: 32090327
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and primary treatment for Waldenström macroglobulinemia - a Swedish Lymphoma Registry study.
Brandefors L; Melin B; Lindh J; Lundqvist K; Kimby E
Br J Haematol; 2018 Nov; 183(4):564-577. PubMed ID: 30198549
[TBL] [Abstract][Full Text] [Related]
4. Patterns of survival in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia: a population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005.
Kristinsson SY; Eloranta S; Dickman PW; Andersson TM; Turesson I; Landgren O; Björkholm M
Am J Hematol; 2013 Jan; 88(1):60-5. PubMed ID: 23165980
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression.
Cao X; Medeiros LJ; Xia Y; Wang X; Thomas SK; Loghavi S; Li X; Shah JJ; Gustafson SA; Weber DM; Miranda RN; Xu-Monette ZY; Orlowski RZ; Young KH
Leuk Lymphoma; 2016 May; 57(5):1104-13. PubMed ID: 26421453
[TBL] [Abstract][Full Text] [Related]
6. Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia.
Olszewski AJ; Chen C; Gutman R; Treon SP; Castillo JJ
Br J Haematol; 2017 Oct; 179(1):106-115. PubMed ID: 28677830
[TBL] [Abstract][Full Text] [Related]
7. Elevated risk of venous but not arterial thrombosis in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Hultcrantz M; Pfeiffer RM; Björkholm M; Goldin LR; Turesson I; Schulman S; Landgren O; Kristinsson SY
J Thromb Haemost; 2014 Nov; 12(11):1816-21. PubMed ID: 25196979
[TBL] [Abstract][Full Text] [Related]
8. Conditional relative survival in Waldenström's macroglobulinaemia: a population-based study in The Netherlands.
Amaador K; Kersten MJ; Visser O; Posthuma EFM; Minnema MC; Vos JMI; Dinmohamed AG
Br J Haematol; 2022 Mar; 196(5):1205-1208. PubMed ID: 34738239
[TBL] [Abstract][Full Text] [Related]
9. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia.
Castillo JJ; Gustine JN; Meid K; Dubeau TE; Severns P; Xu L; Yang G; Hunter ZR; Treon SP
Br J Haematol; 2018 Apr; 181(1):77-85. PubMed ID: 29468652
[TBL] [Abstract][Full Text] [Related]
10. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database.
Castillo JJ; Olszewski AJ; Kanan S; Meid K; Hunter ZR; Treon SP
Br J Haematol; 2015 Apr; 169(1):81-9. PubMed ID: 25521528
[TBL] [Abstract][Full Text] [Related]
11. Community-acquired infections associated with increased risk of lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia.
McShane CM; Murray LJ; Engels EA; Anderson LA
Br J Haematol; 2014 Mar; 164(5):653-8. PubMed ID: 24528127
[TBL] [Abstract][Full Text] [Related]
12. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.
Paludo J; Abeykoon JP; Kumar S; Shreders A; Ailawadhi S; Gertz MA; Kourelis T; King RL; Reeder CB; Leung N; Kyle RA; Buadi FK; Habermann TM; Dingli D; Witzig TE; Dispenzieri A; Lacy MQ; Go RS; Lin Y; Gonsalves WI; Warsame R; Lust JA; Rajkumar SV; Ansell SM; Kapoor P
Br J Haematol; 2017 Oct; 179(1):98-105. PubMed ID: 28786474
[TBL] [Abstract][Full Text] [Related]
13. [Clinical features of 16 cases of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia].
Wang JJ; Jing HM; Shen HW; Xu JS; Li M; Gao ZF; Ke XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1494-8. PubMed ID: 21176358
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma.
Cornell RF; Bachanova V; D'Souza A; Woo-Ahn K; Martens M; Huang J; Al-Homsi AS; Chhabra S; Copelan E; Diaz MA; Freytes CO; Gale RP; Ganguly S; Hamadani M; Hildebrandt G; Kamble RT; Kharfan-Dabaja M; Kindwall-Keller T; Lazarus HM; Marks DI; Nishihori T; Olsson RF; Saad A; Usmani S; Vesole DH; Yared J; Mark T; Nieto Y; Hari P
Biol Blood Marrow Transplant; 2017 Jan; 23(1):60-66. PubMed ID: 27789362
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristic and outcome of lymphoplasmacytic lymphoma of non-Waldenstrom macroglobulinemia type: A Swedish lymphoma registry study.
Brandefors L; Sander B; Lundqvist K; Kimby E
Br J Haematol; 2022 Mar; 196(6):1362-1368. PubMed ID: 34959252
[TBL] [Abstract][Full Text] [Related]
16. [The pathology and genetic background of lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia].
Timár B
Magy Onkol; 2017 Mar; 61(1):6-11. PubMed ID: 28273183
[TBL] [Abstract][Full Text] [Related]
17. Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.
Castillo JJ; D'Sa S; Lunn MP; Minnema MC; Tedeschi A; Lansigan F; Palomba ML; Varettoni M; Garcia-Sanz R; Nayak L; Lee EQ; Rinne ML; Norden AD; Ghobrial IM; Treon SP
Br J Haematol; 2016 Mar; 172(5):709-15. PubMed ID: 26686858
[TBL] [Abstract][Full Text] [Related]
18. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.
Paludo J; Abeykoon JP; Shreders A; Ansell SM; Kumar S; Ailawadhi S; King RL; Koehler AB; Reeder CB; Buadi FK; Dispenzieri A; Lacy MQ; Dingli D; Witzig TE; Go RS; Gonsalves WI; Kourelis T; Warsame R; Leung N; Habermann TM; Hayman S; Lin Y; Kyle RA; Rajkumar SV; Gertz MA; Kapoor P
Ann Hematol; 2018 Aug; 97(8):1417-1425. PubMed ID: 29610969
[TBL] [Abstract][Full Text] [Related]
19. Incidence of lymphoplasmacytic lymphoma/Waldenström's macroglobulinaemia in Japan and Taiwan population-based cancer registries, 1996-2003.
Iwanaga M; Chiang CJ; Soda M; Lai MS; Yang YW; Miyazaki Y; Matsuo K; Matsuda T; Sobue T
Int J Cancer; 2014 Jan; 134(1):174-80. PubMed ID: 23784625
[TBL] [Abstract][Full Text] [Related]
20. Lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia: clinicopathological features and differential diagnosis.
Wang W; Lin P
Pathology; 2020 Jan; 52(1):6-14. PubMed ID: 31767130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
